Penny stocks are stocks that trade for less than $5 per share, and they offer investors the opportunity to invest in emerging companies with high growth potential. However, penny stocks also come with high risks, such as low liquidity, high volatility, and limited financial information. Therefore, investors need to be careful and selective when choosing penny stocks to buy.
In this article, we will look at three penny stocks that could deliver massive gains by 2024. These stocks are in sectors that are expected to grow in the future, such as clean energy, biotechnology, and cannabis. They also have strong fundamentals, such as revenue and earnings growth, positive cash flow, and reasonable valuations.
Let’s take a closer look at these three penny stock gems:
Broadwind (BWEN)
Broadwind is a manufacturer of heavy industrial equipment, including equipment for the clean energy sector. The company produces wind towers, gears, and other components for wind turbines, as well as fabrications and services for other industries. Broadwind has been benefiting from the increasing demand for renewable energy sources, especially wind power.
In 2023, Broadwind reported revenue of $199.6 million, up 18% year-over-year, and net income of $8.4 million, compared to a net loss of $13.9 million in 2022. The company also generated positive operating cash flow of $14.7 million, up from $3.6 million in 2022. Broadwind ended the year with a backlog of $236 million, up 28% year-over-year.
Looking ahead, Broadwind expects revenue to grow by 15% to 20% in 2024, driven by strong demand for its products and services. The company also expects to improve its profitability and cash flow as it executes its growth strategy and operational improvements. Broadwind currently trades at $3.66 per share, with a market cap of $67.8 million and a forward price-to-earnings (P/E) ratio of 11.91.
Ardelyx (ARDX)
Ardelyx is a biopharmaceutical company that develops and commercializes innovative therapies for cardiorenal diseases. The company’s lead product is tenapanor, an oral drug that treats hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Hyperphosphatemia is a condition where the blood phosphate levels are too high, which can lead to serious complications such as bone disease and cardiovascular disease.
In 2023, Ardelyx received approval from the U.S. Food and Drug Administration (FDA) for tenapanor under the brand name Ibsrela2. The company also launched the drug in the U.S. market in partnership with Kyowa Kirin Co., Ltd., a Japanese pharmaceutical company that holds the exclusive rights to tenapanor in Japan and other Asian countries. Ardelyx reported revenue of $40.2 million in 2023, up from $16.6 million in 2022, mainly from milestone payments from Kyowa Kirin.
In 2024, Ardelyx expects to generate significant revenue from tenapanor sales in the U.S., as well as additional milestone payments from Kyowa Kirin as the drug progresses in clinical trials in Japan and China. The company also expects to advance its pipeline of other drug candidates for cardiorenal diseases, such as RDX013 for hyperkalemia and RDX047 for metabolic acidosis. Ardelyx currently trades at $3.66 per share, with a market cap of $353 million and a forward price-to-sales (P/S) ratio of 52.
Trulieve Cannabis (TCNNF)
Trulieve Cannabis is a leading medical cannabis company in the U.S., with operations in Florida, California, Massachusetts, Pennsylvania, Connecticut, and West Virginia. The company cultivates, processes, distributes, and sells a variety of cannabis products, such as flower, edibles, concentrates, tinctures, capsules, and topicals. Trulieve has a loyal customer base of over 600,000 patients and a dominant market share of over 50% in Florida.
In 2023, Trulieve reported revenue of $842 million, up 106% year-over-year, and adjusted EBITDA of $355 million, up 99% year-over-year3. The company also generated positive free cash flow of $92 million3. Trulieve achieved these impressive results by expanding its production capacity, opening new dispensaries, launching new products, and entering new markets.
In 2024, Trulieve expects to continue its growth trajectory by leveraging its strong brand recognition, operational excellence, and vertical integration. The company also expects to benefit from the legalization of recreational cannabis in some of its key markets, such as Florida and Pennsylvania. Trulieve currently trades at $1.3 per share, with a market cap of $1.3 billion and a forward P/E ratio of 6.83.
Conclusion
These three penny stocks are among the best ones to invest in 2024, as they have solid growth prospects, competitive advantages, and attractive valuations. However, investors should be aware of the risks involved in trading penny stocks, such as high volatility, low liquidity, and limited information. Therefore, investors should do their own due diligence, diversify their portfolio, and use stop-loss orders to protect their capital.
Disclaimer: The information contained in this article is for informational purposes only and should not be construed as investment advice or an endorsement of any particular stock. Investors should consult a financial professional before making any investment decisions.
0 Comments